Etidoxina

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Etidoxina

Understanding Etidoxina

Etidoxina is a pharmaceutical formulation that combines two distinct active therapeutic agents: etofylline and doxycycline. This combination is designed to address specific physiological needs by pairing a bronchodilator with a broad-spectrum antibiotic.

Components and Mechanisms

The efficacy of Etidoxina is derived from its dual-action composition:

  • Etofylline: This component belongs to the xanthine derivative family. It functions primarily by relaxing the smooth muscles of the bronchial airways and stimulating the respiratory center. Its role is to facilitate easier breathing by reducing airway resistance.
  • Doxycycline: A member of the tetracycline class, doxycycline is a bacteriostatic antibiotic. It works by inhibiting the protein synthesis of susceptible bacteria, preventing them from growing and replicating within the body.

Therapeutic Purpose

Etidoxina is primarily utilized in the management of respiratory conditions where both an underlying bacterial infection and airway obstruction are present. By addressing these two factors simultaneously, the medication aims to clear the infection while improving the patient's ventilatory capacity.

Commonly associated conditions include:

  • Acute exacerbations of chronic bronchitis.
  • Infectious complications related to chronic obstructive pulmonary disease (COPD).
  • Bacterial pneumonia involving bronchial constriction.

Pharmacological Profile

When administered, the components are absorbed through the gastrointestinal tract. Doxycycline is known for its high degree of lipid solubility and its ability to penetrate various body tissues, including the lungs. Etofylline complements this by ensuring the pathways to these tissues remain open, allowing for more effective management of the respiratory system's mechanical and biological health.

Regulatory References

  1. NIH MedlinePlus Drug Information on Doxycycline
  2. WHO Essential Medicines Lists
  3. Doxycycline on WHO Essential Medicines List (eEML)

What side effects are possible with Etidoxina?

Possible Side Effects and Safety Information

The safety profile of Etidoxina (Doxycycline/Bromhexine) is based on findings documented in regulatory sources and official prescribing information. Side effects are categorized by frequency and the body system affected.


Key Adverse Reactions

Adverse reactions commonly involve the gastrointestinal system, presenting as nausea, vomiting, or diarrhea. A frequent and notable concern is photosensitivity, which is an exaggerated skin reaction to sunlight or UV light, resulting in a severe sunburn-like response.


Serious and Rare Risks

Official documents warn of rare but serious reactions requiring immediate medical attention, including anaphylaxis and other severe systemic hypersensitivity reactions. Severe and potentially life-threatening skin conditions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have also been reported. Other serious but reversible effects include benign intracranial hypertension (increased pressure in the head, causing severe headache and vision changes) and Clostridium difficile-associated diarrhea (CDAD), which can occur during or after treatment.


Safety Restrictions for Specific Populations

Use is generally restricted or contraindicated in children under 8 years old due to the risk of permanent discoloration of developing teeth and potential effects on bone growth. Similarly, the medicine is discouraged during pregnancy and breastfeeding for similar developmental risks to the fetus or infant. Patients are restricted from taking the drug with antacids or iron supplements as these products prevent the medicine from being properly absorbed.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Etidoxina (Doxycycline) primarily as an increased incidence of known side effects, affecting the central nervous system and the gastrointestinal tract.


Documented Manifestations and Severe Outcomes

Domain Regulatory Documentation
Expected Presentations Manifestations commonly include gastrointestinal disturbances (nausea, vomiting, diarrhea) and the potential for Intracranial Hypertension (IH), which may present as headache and visual disturbances [NIH MedlinePlus Doxycycline].
Severe Outcomes Officially documented severe risks include permanent visual loss secondary to uncontrolled Intracranial Hypertension, and the potential for fatal colitis associated with Clostridium difficile-associated diarrhea [FDA Prescribing Information Doxycycline].
Population Note Overweight women of childbearing age or those with a history of IH are noted to be at greater risk for IH complications [FDA Prescribing Information Doxycycline].

Mandated Emergency Actions

Required Action Official Regulatory Statement
Immediate Help Patients must seek immediate medical attention following any accidental overexposure or overdose [NIH MedlinePlus Doxycycline]. Immediate care is mandated if symptoms such as visual disturbance occur [FDA Prescribing Information Doxycycline].
Management Overdose treatment is limited to symptomatic and supportive treatment. Official labels state that no specific antidote is known for Doxycycline overdose [EMA SmPC Doxycycline]. Procedures such as gastric lavage may be initiated to reduce systemic absorption [EMA SmPC Doxycycline].
Monitoring Note Patients with symptoms of Intracranial Hypertension must be monitored until stabilization [FDA Prescribing Information Doxycycline]. Dialysis is not expected to be beneficial as it does not significantly alter the drug's half-life [EMA SmPC Doxycycline].

Therapeutic Uses of Etidoxina

What Etidoxina Treats: Main Uses and Benefits

Etidoxina (Doxycycline) is primarily used for its capacity to address specific groups of symptoms related to systemic imbalance arising from susceptible bacterial infections, supporting comfort in acute situations. The core benefit provided is managing the progression of the underlying bacterial cause, which provides support that helps ease the overall symptom burden associated with the illness. This medication is applied across domains where additional symptomatic support is needed.

Etidoxina is commonly used in conditions presenting with systemic or localized discomfort. Key therapeutic areas include managing systemic vector-borne diseases (such as Lyme disease and Rocky Mountain spotted fever) and specific sexually transmitted infections (including Chlamydia, Syphilis, and Gonorrhea when required). It also addresses pronounced inflammatory skin conditions (like severe acne and papulopustular rosacea), helping to reduce the number and severity of inflammatory lesions. In high-risk contexts, it assists with supportive management during situations of Malaria prevention or post-exposure regimens.

Quick Fact: Supportive Relief for Symptom Clusters
Primary Benefit Supportive relief for conditions linked to bacterial presence.
Symptom Focus Fever, malaise, discharge, inflammatory skin lesions.
Clinical Context Acute systemic illness, chronic skin conditions, prophylaxis.
Patient Support Contributes to supporting comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility to use Etidoxina (Doxycycline) is strictly defined by government regulatory agencies based on age, physiological status, and underlying medical conditions.

Eligibility and Population Restrictions

Classification Rule (Official Regulatory Status)
Allowed Adults and children 8 years of age and older are generally eligible for use.
Contraindicated (Must Not Use) Individuals with known hypersensitivity to Doxycycline or any tetracycline antibiotic.
Contraindicated (Must Not Use) Pregnant women due to the risk of fetal dental and skeletal effects.
Prohibited/Restricted Children under 8 years of age are generally prohibited due to the risk of permanent tooth discoloration, except in specific life-threatening scenarios where benefits outweigh the risks (e.g., severe rickettsial disease).
Not Recommended Breastfeeding individuals, as the drug is excreted in milk, requiring careful risk-benefit evaluation.
Conditional Use Patients with severe hepatic (liver) impairment require caution and may necessitate lower doses, as noted in the European Summary of Product Characteristics (SmPC).

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes clinically significant interactions for [Etidoxina] as documented in official regulatory labeling.

Contraindicated and High-Risk Combinations

  • Penicillins: Co-administration is generally avoided due to the potential for interference with the bactericidal action of penicillin.
  • Retinoids (e.g., Isotretinoin): Combination use carries an officially documented increased risk of pseudotumor cerebri (benign intracranial hypertension) and should be avoided.

Interactions Affecting Drug Exposure

The following substances can reduce the systemic concentration of [Etidoxina] by impairing its absorption or increasing its clearance:

  • Substances containing Metal Cations: Antacids containing aluminum, calcium, or magnesium, and iron-containing preparations (including supplements) can bind to the drug, significantly reducing absorption.
  • Bismuth Subsalicylate: This substance also impairs absorption, leading to lower serum concentrations.
  • Certain Anticonvulsants (e.g., Phenytoin, Carbamazepine, Phenobarbital): These medicines are documented to decrease the drug's half-life, which may result in sub-therapeutic plasma levels.

Pharmacodynamic Interactions

  • Oral Anticoagulants (e.g., Warfarin): [Etidoxina] may depress plasma prothrombin activity. Patients on concurrent anticoagulant therapy require careful monitoring of their prothrombin time (e.g., INR) and may require a downward adjustment of the anticoagulant dosage.

Mechanism of Action

How Etidoxina Works

Etidoxina (Doxycycline) operates through a distinct dual mechanism that influences both bacterial viability and host inflammatory response.

Blocking Bacterial Growth at the Molecular Level

The primary antibacterial action involves targeting the 30S ribosomal subunit inside susceptible bacteria. By binding to this crucial structure, Doxycycline physically blocks the binding of aminoacyl-tRNA to the A-site, thereby arresting the necessary polypeptide chain elongation and shutting down bacterial protein synthesis. This mechanism produces a bacteriostatic state by preventing the pathogen population from increasing.

Modulating Host Inflammatory Damage

Independent of its action against bacteria, Doxycycline exerts effects on host physiology by acting as an inhibitor of human Matrix Metalloproteinase (MMP) enzymes. This occurs through chelation of the metal ions required for MMP activity. By reducing the activity of these enzymes, the drug modulates the degradation of structural components in host tissue, such as collagen, which occurs during inflammatory processes. This results in the modulation of activity within the targeted physiological pathways.

Dosage and Administration Information

Official Administration Guidelines

Etidoxina (Doxycycline) is administered via oral forms (capsules, tablets) for most uses, or as a sterile Intravenous (IV) solution when oral intake is not feasible. Usage is governed by a precise schedule and specific instructions detailed in regulatory documents.


Feature Official Labeled Instruction
Standard Adult Dose (Acute) 200 mg on the first day, typically divided into two 100 mg doses, followed by a 100 mg maintenance dose daily.
Frequency Pattern Once daily for maintenance/prophylaxis, or twice daily for the loading dose or in the management of more severe infections.
Duration of Use Varies by condition; therapy is typically continued for at least 24 to 48 hours after symptoms subside, or for fixed courses (e.g., 7 days for certain infections).
Pediatric Dosing Rule For children weighing 45 kg or less, dosing is weight-based, starting at 4.4 mg/kg divided on the first day. Children over 45 kg receive the usual adult dose.

Procedural and Contextual Intake Rules

For oral administration, capsules or tablets must be swallowed with an adequate amount of fluid (e.g., at least 100 mL of water) while the patient is in a sitting or standing position. Patients are instructed to remain upright for at least 30 minutes after taking the dose to mitigate the risk of esophageal irritation.

Oral forms may generally be taken with or without food; however, regulatory documents recommend taking the medicine with food or milk if gastric upset occurs. To maintain effective levels, absorption of the medicine is impaired by concurrent use of products containing iron, calcium supplements, or antacids; these should be separated from the Doxycycline dose. If a dose is missed, it should be taken as soon as remembered, but a patient must not take a double dose to compensate for the missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Etidoxina

The research on Etidoxina (Doxycycline) is primarily documented in official regulatory records, clinical guidelines, and peer-reviewed scientific literature, including both Randomized Controlled Trials (RCTs) and large systematic reviews. This overview focuses on the structure of that evidence—what was studied and what patterns researchers observed—without offering any personal guidance or clinical advice.


Evidence for Use in Specific Bacterial Infections (Systemic Use)

Research has widely studied Etidoxina's use for specific systemic bacterial diseases, including Rickettsial and Vector-Borne Diseases (like Lyme disease) and treatment for certain Bacterial Sexually Transmitted Infections (STIs). Studies included short-term RCTs that tracked key outcomes related to physical discomfort and outcomes related to systemic or functional imbalance. Researchers monitored bacterial presence and measured the progression of disease in these settings.

Studies conducted during periods of increased symptom activity reported that a high proportion of patients receiving the treatment showed measurements of change in acute symptoms, such as fever reduction. Systematic reviews of treatment studies reported measurements of bacterial presence across the specific infections studied. The research basis includes older, well-documented clinical datasets, and comparative evidence is lacking against some of the newest agents for these specific conditions.


Evidence for Use in Inflammatory Skin Conditions

The evidence base for Etidoxina’s application in the management of specific pronounced inflammatory conditions, such as Acne Vulgaris and Rosacea, is supported by numerous intermediate-term Randomized Controlled Trials (RCTs). These trials explored the medicine's role in managing conditions characterized by fluctuating or episodic manifestations linked to inflammatory states. Researchers focused on outcomes linked to inflammatory or irritative states, specifically measuring changes in the number and severity of lesions and using standardized assessment tools.


Understanding Long-Term Study Follow-up and Durability

The research examined whether the observed outcomes persist after the initial short-term treatment period concludes. The follow-up durations were limited for many acute infection studies, focusing mainly on the successful resolution of the initial illness. For chronic conditions, studies have explored maintenance strategies and tracked patients for intermediate periods to look for patterns of recurrence. Long-term outcomes are not well characterized for all indications, meaning that the evidence primarily contributes to understanding symptom patterns during and immediately following treatment.

Frequently Asked Questions (FAQ)

Common questions about Etidoxina (FAQ)


Q: How quickly does Etidoxina start working after the first dose?

Official information indicates that Doxycycline, the active ingredient, begins to inhibit bacterial growth and reduce inflammation typically within the first 24 to 48 hours of treatment. The timeframe for symptom improvement may vary depending on the specific condition being addressed.


Q: What happens if I accidentally miss a dose of Etidoxina?

If a dose is missed, regulatory information advises taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, it is generally advised to skip the missed one and return to the regular schedule. Regulatory warnings indicate that a double dose must not be taken to compensate for a missed one.


Q: How long does a typical course of Etidoxina treatment last?

The length of treatment varies significantly based on the condition being addressed. For acute infections, courses often last around 7 days, or at least 24 to 48 hours after symptoms have stopped. For certain chronic conditions, the medicine may be used for a longer-term period as specified by official regulatory guidelines.


Q: Does Etidoxina cause sensitivity to sunlight (photosensitivity)?

Yes, regulatory documents warn that this medicine can cause a severe skin reaction called photosensitivity, which is an exaggerated response to sunlight or UV light. This phototoxic reaction can resemble a severe sunburn. Protective measures against sun exposure are often recommended in the official information to help minimize this risk.


Q: Is it normal to have a headache when starting Etidoxina?

Headache is a reported side effect of Doxycycline. Official safety labels also include warnings about a rare but serious condition called benign intracranial hypertension (increased pressure in the head), which can manifest as a severe, persistent headache. Official safety information recommends monitoring any severe or persistent headache.


Q: How does Etidoxina's effectiveness compare to older treatments for the same condition?

Regulatory reviews indicate that Doxycycline has demonstrated similar effectiveness to other standard, older treatments for specific infections. Clinical data also suggests it may sometimes show a lower incidence of certain gastrointestinal side effects, such as nausea, compared to other drug formulations.


Q: How long does Etidoxina stay in your system after the last pill?

The elimination half-life of Doxycycline is typically between 16 and 22 hours. This is the time it takes for the concentration of the drug in the body to reduce by half. It generally takes about 5 days for the drug to be almost completely eliminated from a healthy adult's system.


Q: Can Etidoxina make you feel tired or dizzy?

Official safety documentation reports dizziness as a possible symptom associated with Doxycycline use. The safety label documentation notes warnings for potential side effects affecting the central nervous system (CNS), which may include fatigue or drowsiness.


Q: Can children or teenagers take Etidoxina?

Official guidelines state that the medicine is generally allowed for individuals 8 years of age and older, including teenagers. Dosing for children under 45 kg is typically determined based on body weight.


Q: Is Etidoxina safe for older adults (seniors)?

Regulatory information indicates that no specific geriatric-related issues limit the general use of this medicine. Caution is often mentioned, especially for patients with pre-existing heart, liver, or kidney issues, as dosage review may be required.


Q: Do you have to take Etidoxina with food?

No, taking the medicine with food is generally not required for its effectiveness. Official administration guidelines indicate that it may be taken with food or milk if the medicine causes stomach upset or nausea, as this can help minimize gastric discomfort.


Q: Are there any specific supplements that interact with Etidoxina?

Yes, supplements containing metal cations are known to interact with Doxycycline. Specifically, supplements containing iron, calcium, magnesium, and zinc can bind to the medicine, significantly reducing its absorption. To avoid impaired absorption, these supplements are recommended to be separated from the Doxycycline dose by at least 3 hours.


Q: What are the signs of a serious allergic reaction to Etidoxina?

Serious reactions like anaphylaxis or severe skin conditions (e.g., Stevens-Johnson syndrome) are rare but require immediate medical attention. Signs may include the sudden appearance of blisters, peeling skin, a rash of small purple spots, or severe swelling of the face, throat, or tongue.


Q: How is Etidoxina stored, and does it need to be refrigerated?

Official instructions mandate that the medicine should be stored in a closed container at Controlled Room Temperature (typically 20 C to 25 C), away from heat and moisture. It is important that the medicine not be frozen and it does not typically need to be refrigerated.


Q: Can Etidoxina impact dental health or tooth color?

For adults, the medicine may sometimes cause temporary discoloration of teeth, which is often reversible with professional dental cleaning after treatment is finished. The risk of permanent discoloration (yellow-gray-brown) of developing teeth applies only to children under 8 years old.


Q: Is Etidoxina the same as Doxycycline, or is it different?

Etidoxina is a common brand name for the medicine that contains the active ingredient Doxycycline. Regulatory documents and scientific literature confirm that both names refer to the same tetracycline antibiotic drug, which is the core therapeutic component.


Q: Can Etidoxina be crushed or chewed, or must it be swallowed whole?

Oral forms like tablets and capsules must be swallowed whole with adequate fluid. For safety and effectiveness, these forms are not intended to be cut, crushed, or chewed, as this can cause irritation of the food pipe (esophagus) and affect the intended way the medicine is absorbed.


Q: Does Etidoxina affect the gut microbiome?

As a broad-spectrum antibiotic, the use of Doxycycline can cause changes in the gut microbiome (the normal bacterial population in the digestive tract). Changes in the microbiome can sometimes lead to common side effects like diarrhea, or, rarely, a more serious condition called Clostridium difficile-associated diarrhea (CDAD).


Q: Is it possible to develop resistance to Etidoxina over time?

Yes, the development of antibiotic resistance is a known risk associated with Doxycycline and all antibacterial drugs. Official warnings emphasize that the medicine is indicated only for treating susceptible bacterial infections.


Q: Does Etidoxina interact with alcohol, and how severe is the risk?

Regulatory documents suggest that consuming alcohol, especially excessive or chronic use, may potentially reduce the overall effectiveness of Doxycycline. Alcohol consumption may also increase the risk of experiencing some common side effects, such as dizziness and stomach upset.


Q: If I have a history of ulcers, can I still take Etidoxina?

While the medicine itself is associated with a risk of esophageal irritation and ulceration, specific guidance focuses on prevention. Regulatory instructions stress the importance of taking the medicine with a full glass of water and remaining in a sitting or standing position for at least 30 minutes after taking the dose to minimize irritation.


Q: Why is the research evidence for Etidoxina sometimes described as limited?

Regulatory overviews sometimes point out that the evidence base has gaps. This usually means that long-term outcomes (what happens many months or years after treatment) are not well characterized for all indications, or that comparative evidence is lacking against some of the newest alternative treatment agents.


Q: What are the typical benefits people experience from Etidoxina?

The medicine is intended to stop the progression of susceptible bacterial infections, such as those affecting the chest or sexually transmitted infections, and to manage inflammatory states in skin conditions like acne and rosacea. The benefits are generally related to the successful treatment or prevention of these specific conditions.

How should Etidoxina be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents mandate specific conditions for storing and disposing of Etidoxina (Doxycycline) to maintain its integrity and stability.


Storage Conditions

Requirement Official Regulatory Mandate
Temperature Store at Controlled Room Temperature (20 C to 25 C), with excursions permitted between 15 C and 30 C.
Container Must be dispensed in a tight container.
Child-Safety Keep out of reach of children.

Disposal Instructions

Unused or expired Etidoxina must be disposed of according to local regulations. No specific instructions for environmental or hazardous waste are universally cited in the primary labeling; compliance with local pharmaceutical disposal guidelines is required.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Etidoxina found in:

A-Z Index: